- Home
- HOOD vs AMGN Comparison
HOOD vs AMGN Comparison
Compare HOOD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOD
- AMGN
- Stock Information
- Founded
- HOOD 2013
- AMGN 1980
- Country
- HOOD United States
- AMGN United States
- Employees
- HOOD N/A
- AMGN N/A
- Industry
- HOOD Computer Software: Prepackaged Software
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOOD Technology
- AMGN Health Care
- Exchange
- HOOD Nasdaq
- AMGN Nasdaq
- Market Cap
- HOOD 127.2B
- AMGN 150.8B
- IPO Year
- HOOD 2021
- AMGN N/A
- Fundamental
- Price
- HOOD $130.49
- AMGN $298.75
- Analyst Decision
- HOOD Buy
- AMGN Buy
- Analyst Count
- HOOD 23
- AMGN 18
- Target Price
- HOOD $111.48
- AMGN $326.94
- AVG Volume (30 Days)
- HOOD 31.6M
- AMGN 2.4M
- Earning Date
- HOOD 11-05-2025
- AMGN 11-04-2025
- Dividend Yield
- HOOD N/A
- AMGN 3.19%
- EPS Growth
- HOOD 513.62
- AMGN 110.88
- EPS
- HOOD 1.96
- AMGN 12.23
- Revenue
- HOOD $3,567,000,000.00
- AMGN $34,917,000,000.00
- Revenue This Year
- HOOD $46.05
- AMGN $8.94
- Revenue Next Year
- HOOD $20.07
- AMGN $1.69
- P/E Ratio
- HOOD $66.12
- AMGN $24.43
- Revenue Growth
- HOOD 59.38
- AMGN 12.88
- 52 Week Low
- HOOD $23.00
- AMGN $253.30
- 52 Week High
- HOOD $153.86
- AMGN $335.88
- Technical
- Relative Strength Index (RSI)
- HOOD 49.11
- AMGN 60.35
- Support Level
- HOOD $133.05
- AMGN $289.44
- Resistance Level
- HOOD $153.56
- AMGN $302.27
- Average True Range (ATR)
- HOOD 7.41
- AMGN 7.04
- MACD
- HOOD -2.51
- AMGN 0.84
- Stochastic Oscillator
- HOOD 17.32
- AMGN 87.56
About HOOD Robinhood Markets Inc.
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.